Key result
Pre-operative hs-cTnI over 6.2 pg/ml linked to ~470% greater 30-day MACE risk after noncardiac surgery.
Why the study?
The study evaluated the predictive value of perioperative hs-cTnI for MACE and all-cause mortality within 30 days and 1 year after noncardiac surgery.
Does perioperative high-sensitivity cardiac troponin I predict MACE and all-cause mortality in patients undergoing noncardiac surgery?
Cohort (n=93)
No
Does perioperative high-sensitivity cardiac troponin I predict MACE and all-cause mortality in patients undergoing noncardiac surgery?
Hazard Ratio: 5.7 (95% CI 1.1–29.4)
Pre-operative hs-cTnI is an independent predictor of 30-day and 1-year MACE and 1-year all-cause mortality after noncardiac surgery.
May refine preoperative risk stratification in noncardiac surgery; leaves open whether hs-cTnI-guided interventions improve outcomes.
BACKGROUND: Various studies suggest that perioperative concentrations of high-sensitivity troponins are incremental and predictive factors of a major adverse cardiac event (MACE) and all-cause mortality. OBJECTIVE: The objective of the study was to evaluate the predictive value of high-sensitivity cardiac troponin I (hs-cTnI) in the development of MACE and all-cause mortality, within 30-days and 1-year follow-up after noncardiac surgery. METHODS: In this prospective cohort study, we included men ≥ 45 years and women ≥ 55 years with ≥ 2 cardiovascular risk factors and undergoing intermediate or high-risk noncardiac surgery. Demographic and clinical information was collected from clinical charts. We measured baseline hs-cTnI 24 h before surgery, and its post-operative concentration 24 h after surgery. RESULTS: In the entire sample, 8 patients (8.6%) developed MACE at 30-days follow-up (4 deaths), 12 (12.9%) within the 1st year (7 deaths), and 17 (18.2%) after complete post-surgical follow-up (10 deaths). We observed higher baseline and post-operative concentrations in patients who presented MACE (12 pg/ml vs. 3.5 pg/ml; p = 0.001 and 18.3 pg/ml vs. 5.45 pg/ml; p = 0.009, respectively). The hazard ratios (HRs) calculated by Cox regression analysis between the hs-cTnI baseline concentration and the post-operative development of MACE at 30-days and 1-year were 5.70 (95% confidence interval [CI], 1.10-29.40) with hs-cTnI > 6.2 pg/ml and 12.86 (95% CI, 1.42-116.34) with hs-cTnI > 3.3 pg/ml, respectively. The estimated post-operative HR death risk at 1-year was 14.43 (95% CI, 1.37-151.61) with hs-cTnI > 4.5 pg/ml. CONCLUSIONS: Pre-operative hs-cTnI was an independent predictive risk factor for MACE at 30-days and 1-year after noncardiac surgery and for all-cause mortality at 1-year after noncardiac surgery.
No takes yet. Share an insight, caveat, or question.
Millán-Figueroa et al. (2020) conducted a cohort in Cardiovascular risk factors in patients undergoing noncardiac surgery (n=93). Pre-operative high-sensitivity cardiac troponin I (hs-cTnI) > 6.2 pg/ml vs. Pre-operative hs-cTnI ≤ 6.2 pg/ml was evaluated on Major adverse cardiac events (MACE) at 30-days follow-up (HR 5.70, 95% CI 1.10-29.40). Pre-operative high-sensitivity cardiac troponin I > 6.2 pg/ml was an independent predictive risk factor for major adverse cardiac events at 30 days after noncardiac surgery (HR 5.70).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: